HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples